Toxoplasma gondii: The Model Apicomplexan - Perspectives and Methods, Third Edition, reflects significant advances in the field in the last five years, including new information on the genomics, epigenomics and proteomics of T. gondii, along with a new understanding of the population biology and genetic diversity of this organism. This edition expands information on the effects of T. gondii on human psychiatric disease and new molecular techniques, such as CAS9/CSPR. T gondii remains the best model system for studying the entire Apicomplexa group of protozoans, which includes Malaria, making this new edition essential for a broad group of researchers and scientists.
1. 3.1 Introduction - p. 63 2. 3.2 Genetic markers - p. 64 3. 3.3 Evolutionary history - p. 77 4. 3.4 Global diversity and population structure - p. 82 5. 3.5 Outbreak investigations - p. 90 6. 3.6 Toxoplasma genotype and biological characteristics - p. 95 7. 3.7 Toxoplasma gondii genotype and human disease - p. 97 8. 3.8 Conclusion and perspective on Toxoplasma genotype and human disease - p. 102 9. Acknowledgments - p. 103 10. References - p. 103 11. Chapter 4. Human Toxoplasma infection - p. 117 12. Abstract - p. 117 13. 4.1 Clinical manifestations and course - p. 117 14. 4.2 Diagnosis of infection with Toxoplasma gondii - p. 143 15. 4.3 Treatment - p. 159 16. 4.4 Prevention - p. 172 17. 4.5 Other considerations of pathogenesis in human infections - p. 174 18. 4.6 Conclusion, unifying concepts, and toward the future - p. 201 19. Acknowledgments - p. 201 20. References - p. 202 21. Further reading - p. 202 22. Chapter 5. Ocular disease due to Toxoplasma gondii - p. 229 23. Abstract - p. 229 24. 5.1 Introduction - p. 229 25. 5.2 Historical landmarks in ocular toxoplasmosis - p. 229 26. 5.3 Epidemiology - p. 231 27. 5.4 Pathophysiology: lessons from animal models and clinical studies - p. 234 28. 5.5 Host factors - p. 236 29. 5.6 Parasite factors - p. 237 30. 5.7 Animal models - p. 240 31. 5.8 Clinical characteristics - p. 241 32. 5.9 Diagnostic tests - p. 257 33. 5.10 Differential diagnosis - p. 267 34. 5.11 The treatment and management of ocular toxoplasmosis - p. 268 35. 5.12 Conclusion - p. 276 36. Acknowledgments - p. 276 37. References - p. 276 38. Chapter 6. Toxoplasmosis in wild and domestic animals - p. 293 39. Chapter 7. Toxoplasma animal models and therapeutics - p. 321 40. Chapter 8. Biochemistry and metabolism of Toxoplasma gondii: lipid synthesis and uptake - p. 367 41. Chapter 9. Biochemistry and metabolism of Toxoplasma gondii: purine and pyrimidine acquisition in Toxoplasma gondii and other Apicomplexa - p. 397 42. Abstract - p. 397 43. 9.1 Introduction - p. 397 44. 9.2 Purines - p. 399 45. 9.3 Pyrimidines - p. 420 46. References - p. 436 47. Further reading - p. 436 48. Chapter 10. Metabolic networks and metabolomics - p. 451 49. Chapter 11. The apicoplast and mitochondrion of Toxoplasma gondii - p. 499 50. Chapter 12. Calcium storage and homeostasis in Toxoplasma gondii - p. 547 51. Chapter 13. Calcium and cyclic nucleotide signaling networks in Toxoplasma gondii - p. 577 52. Chapter 14. Toxoplasma secretory proteins and their roles in parasite cell cycle and infection - p. 607 53. Abstract - p. 607 54. 14.1 Introduction - p. 607 55. 14.2 Motility and invasion - p. 609 56. 14.3 Parasitophorous vacuole formation and maturation - p. 614 57. 14.4 Egress - p. 618 58. 14.5 Micronemes - p. 618 59. 14.6 Rhoptries - p. 642 60. 14.7 Dense granules - p. 668 61. 14.8 Conclusion - p. 684 62. Acknowledgments - p. 684 63. References - p. 684 64. Chapter 15. Endomembrane trafficking pathways in Toxoplasma - p. 705 65. Chapter 16. The Toxoplasma cytoskeleton: structures, proteins, and processes - p. 743 66. Chapter 17. Effectors produced by rhoptries and dense granules: an intense conversation between parasite and host in many languages - p. 789 67. Chapter 18. Bradyzoite and sexual stage development - p. 807 68. Abstract - p. 807 69. 18.1 Introduction - p. 807 70. 18.2 Bradyzoite and tissue cyst morphology and biology - p. 809 71. 18.3 The development of tissue cysts and bradyzoites in vitro - p. 814 72. 18.4 The cell cycle and bradyzoite development - p. 818 73. 18.5 The stress response and signaling pathways for bradyzoite formation - p. 820 74. 18.6 Heat shock proteins - p. 823 75. 18.7 Transcriptional control of bradyzoite genes - p. 826 76. 18.8 Cyst wall and matrix antigens - p. 829 77. 18.9 Surface antigens - p. 834 78. 18.10 Metabolic differences between bradyzoites and tachyzoites - p. 836 79. 18.11 Genetic studies on bradyzoite biology - p. 839 80. 18.12 Sexual stage morphology, biology, and antigens - p. 841 81. 18.13 Sexual stage development in cell culture - p. 842 82. 18.14 Sexual stage development in a mouse model - p. 844 83. 18.15 Summary - p. 844 84. Acknowledgments - p. 845 85. References - p. 845 86. Further reading - p. 845 87. Chapter 19. Development and application of classical genetics in Toxoplasma gondii - p. 859 88. Chapter 20. Genetic manipulation of Toxoplasma gondii - p. 897 89. Chapter 21. Regulation of gene expression in Toxoplasma gondii - p. 941 90. Chapter 22. Proteomics and posttranslational protein modifications in Toxoplasma gondii - p. 983 91. Chapter 23. ToxoDB: the functional genomic resource for Toxoplasma and related organisms - p. 1021 92. Chapter 24. Cerebral toxoplasmosis - p. 1043 93. Chapter 25. Innate immunity to Toxoplasma gondii - p. 1075 94. Chapter 26. Adaptive immunity - p. 1107 95. Appendix A. The effect of murine gene deficiencies on the outcome of Toxoplasma gondii infection - p. 1147 96. Epilogue - p. 1183 97. Index - p. 1185
Toxoplasma gondii: The Model Apicomplexan - Perspectives and Methods, Third Edition, reflects significant advances in the field in the last five years, including new information on the genomics, epigenomics and proteomics of T. gondii, along with a new understanding of the population biology and genetic diversity of this organism. This edition expands information on the effects of T. gondii on human psychiatric disease and new molecular techniques, such as CAS9/CSPR. T gondii remains the best model system for studying the entire Apicomplexa group of protozoans, which includes Malaria, making this new edition essential for a broad group of researchers and scientists.
1. 3.1 Introduction - p. 63 2. 3.2 Genetic markers - p. 64 3. 3.3 Evolutionary history - p. 77 4. 3.4 Global diversity and population structure - p. 82 5. 3.5 Outbreak investigations - p. 90 6. 3.6 Toxoplasma genotype and biological characteristics - p. 95 7. 3.7 Toxoplasma gondii genotype and human disease - p. 97 8. 3.8 Conclusion and perspective on Toxoplasma genotype and human disease - p. 102 9. Acknowledgments - p. 103 10. References - p. 103 11. Chapter 4. Human Toxoplasma infection - p. 117 12. Abstract - p. 117 13. 4.1 Clinical manifestations and course - p. 117 14. 4.2 Diagnosis of infection with Toxoplasma gondii - p. 143 15. 4.3 Treatment - p. 159 16. 4.4 Prevention - p. 172 17. 4.5 Other considerations of pathogenesis in human infections - p. 174 18. 4.6 Conclusion, unifying concepts, and toward the future - p. 201 19. Acknowledgments - p. 201 20. References - p. 202 21. Further reading - p. 202 22. Chapter 5. Ocular disease due to Toxoplasma gondii - p. 229 23. Abstract - p. 229 24. 5.1 Introduction - p. 229 25. 5.2 Historical landmarks in ocular toxoplasmosis - p. 229 26. 5.3 Epidemiology - p. 231 27. 5.4 Pathophysiology: lessons from animal models and clinical studies - p. 234 28. 5.5 Host factors - p. 236 29. 5.6 Parasite factors - p. 237 30. 5.7 Animal models - p. 240 31. 5.8 Clinical characteristics - p. 241 32. 5.9 Diagnostic tests - p. 257 33. 5.10 Differential diagnosis - p. 267 34. 5.11 The treatment and management of ocular toxoplasmosis - p. 268 35. 5.12 Conclusion - p. 276 36. Acknowledgments - p. 276 37. References - p. 276 38. Chapter 6. Toxoplasmosis in wild and domestic animals - p. 293 39. Chapter 7. Toxoplasma animal models and therapeutics - p. 321 40. Chapter 8. Biochemistry and metabolism of Toxoplasma gondii: lipid synthesis and uptake - p. 367 41. Chapter 9. Biochemistry and metabolism of Toxoplasma gondii: purine and pyrimidine acquisition in Toxoplasma gondii and other Apicomplexa - p. 397 42. Abstract - p. 397 43. 9.1 Introduction - p. 397 44. 9.2 Purines - p. 399 45. 9.3 Pyrimidines - p. 420 46. References - p. 436 47. Further reading - p. 436 48. Chapter 10. Metabolic networks and metabolomics - p. 451 49. Chapter 11. The apicoplast and mitochondrion of Toxoplasma gondii - p. 499 50. Chapter 12. Calcium storage and homeostasis in Toxoplasma gondii - p. 547 51. Chapter 13. Calcium and cyclic nucleotide signaling networks in Toxoplasma gondii - p. 577 52. Chapter 14. Toxoplasma secretory proteins and their roles in parasite cell cycle and infection - p. 607 53. Abstract - p. 607 54. 14.1 Introduction - p. 607 55. 14.2 Motility and invasion - p. 609 56. 14.3 Parasitophorous vacuole formation and maturation - p. 614 57. 14.4 Egress - p. 618 58. 14.5 Micronemes - p. 618 59. 14.6 Rhoptries - p. 642 60. 14.7 Dense granules - p. 668 61. 14.8 Conclusion - p. 684 62. Acknowledgments - p. 684 63. References - p. 684 64. Chapter 15. Endomembrane trafficking pathways in Toxoplasma - p. 705 65. Chapter 16. The Toxoplasma cytoskeleton: structures, proteins, and processes - p. 743 66. Chapter 17. Effectors produced by rhoptries and dense granules: an intense conversation between parasite and host in many languages - p. 789 67. Chapter 18. Bradyzoite and sexual stage development - p. 807 68. Abstract - p. 807 69. 18.1 Introduction - p. 807 70. 18.2 Bradyzoite and tissue cyst morphology and biology - p. 809 71. 18.3 The development of tissue cysts and bradyzoites in vitro - p. 814 72. 18.4 The cell cycle and bradyzoite development - p. 818 73. 18.5 The stress response and signaling pathways for bradyzoite formation - p. 820 74. 18.6 Heat shock proteins - p. 823 75. 18.7 Transcriptional control of bradyzoite genes - p. 826 76. 18.8 Cyst wall and matrix antigens - p. 829 77. 18.9 Surface antigens - p. 834 78. 18.10 Metabolic differences between bradyzoites and tachyzoites - p. 836 79. 18.11 Genetic studies on bradyzoite biology - p. 839 80. 18.12 Sexual stage morphology, biology, and antigens - p. 841 81. 18.13 Sexual stage development in cell culture - p. 842 82. 18.14 Sexual stage development in a mouse model - p. 844 83. 18.15 Summary - p. 844 84. Acknowledgments - p. 845 85. References - p. 845 86. Further reading - p. 845 87. Chapter 19. Development and application of classical genetics in Toxoplasma gondii - p. 859 88. Chapter 20. Genetic manipulation of Toxoplasma gondii - p. 897 89. Chapter 21. Regulation of gene expression in Toxoplasma gondii - p. 941 90. Chapter 22. Proteomics and posttranslational protein modifications in Toxoplasma gondii - p. 983 91. Chapter 23. ToxoDB: the functional genomic resource for Toxoplasma and related organisms - p. 1021 92. Chapter 24. Cerebral toxoplasmosis - p. 1043 93. Chapter 25. Innate immunity to Toxoplasma gondii - p. 1075 94. Chapter 26. Adaptive immunity - p. 1107 95. Appendix A. The effect of murine gene deficiencies on the outcome of Toxoplasma gondii infection - p. 1147 96. Epilogue - p. 1183 97. Index - p. 1185
